Cardiac amyloidosis is a rare disease characterized by the accumulation of plaques of the amyloid protein in the heart, making it hard (which is why it is also called stiff heart syndrome) and may require a pacemaker or be the cause of death. It has some treatments, but they are...
Latest News
New York, NY – A large language model artificial intelligence system can match, or in some cases outperform, human ophthalmologists in the diagnosis and treatment of patients with glaucoma and retina disease, according to research from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The provocative study, published...
SAN DIEGO – Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Michael E. Faerm as Chief Financial Officer. Mr. Faerm brings more than 20 years of life sciences, equity research, and investment...
SAN DIEGO, Calif. — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK® (also known as AB-101) for...
NEW YORK and BASEL, Switzerland – Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company’s strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and...
NEW HAVEN, Conn. — Arvinas Inc., (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company’s first oral PROTAC® (PROteolysis-TArgeting Chimera) protein degrader in development...
INDIANAPOLIS – Nancrede Engineering’s experience shows that just when you thought it was safe to return to the office or go on vacation, nature has another deadly surprise waiting for you: Legionnaires’ disease. “When a facility is closed or at low occupancy, Legionella bacteria can grow. As offices and hotels reopen, visitors...
Paris, France – The pathogenic potential of inhaling the inert fibrous nanomaterials used in thermal insulation (such as asbestos or fibreglass) is actually connected not to their chemical composition, but instead to their geometrical characteristics and size. This was revealed by a study, published in the journal Nature Nanotechnology, conducted...
MILPITAS, Calif. – ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ASC618, an...
COPENHAGEN, Denmark — Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology...